ERBB2 and breast carcinoma: Particularly in the context of targeted therapy for HER2-positive breast cancer, drug resistance caused by autophagy is more serious when using the monoclonal antibody Herceptin and epidermal growth factor receptor tyrosine kinase inhibitors like lapatinib [65].